Pharmaceutical Executive
To convey how quickly Alcon's Vigamox resolves pink eye, Corbett Worldwide Healthcare Communications turned to a universally understood icon-the pink eraser-and leveraged it to make the brand stand out in the competitive market.
PINK ERASER
Corbett
BRAND Vigamox CLIENT Alcon FROM LEFT: Eric Loeb, group creative director; Jaime Goldman, senior account director; Peg Gill, copywriter; Cassie Zablotney, account supervisor; Terry Barich, art director; Christina HIllestad, senior project director; Emily Deming, account executive
To convey how quickly Alcon's Vigamox resolves pink eye, Corbett Worldwide Healthcare Communications turned to a universally understood icon—the pink eraser—and leveraged it to make the brand stand out in the competitive market.
The resulting creative used the school-related item to convey how Vigamox could "erase" the disease, and used the word "pink" and the color to link Vigamox to the condition. But what really makes the ad stand out is the childlike illustration style, which puts Vigamox in the world of the pink-eye patients whom doctors see most often.
This deceptively simple concept led to many highly engaging tactics, all using the iconic pink eraser. The two-page medical journal ad took first place in its category at the 2008 Doctor's Choice Awards and was voted most creative at Corbett's 2007 Gallery Awards, an in-house celebration of the agency's best work.
Robin Shapiro, executive vice president, chief creative officer, credits the Corbett team's success with this campaign to the company's unusual philosophy. "Our strategy is to encourage a healthy collision of consumer and pharma talent. We believe that the integration of consumer brand-building expertise with pharma experience enables us to create powerful branding campaigns built around strong scientific insight."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.